Overview

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

Status:
Active, not recruiting

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

The aims of this study are to obtain pharmacokinetic data on interactions between dolutegravir (DTG) and immunosuppressant drugs (Cyclosporine A, Tacrolimus, Sirolimus and Mycophenolic acid) in solid organ transplant (SOT) recipients to provide proof of principle data that DTG plus 2 nucleosides (NUCs) is safe and effective in HIV-infected SOT recipients.

Phase:

Phase 4

Details

Lead Sponsor:

Fundacion Clinic per a la Recerca Biomédica

Treatments:

Abacavir
Dolutegravir
Emtricitabine
Lamivudine
Reverse Transcriptase Inhibitors
Tenofovir